QDENGA Dengue Vaccine: India’s First Approved Dengue Vaccine

What is QDENGA?

• QDENGA (TAK-003) is a live attenuated, tetravalent dengue vaccine developed by Japan-based Takeda.
• It targets all four dengue virus serotypes:
  • DENV-1
  • DENV-2
  • DENV-3
  • DENV-4
• WHO prequalified: 2024.
• Dosing: 2 doses, administered 3 months apart.
• Dengue infection testing is not required before vaccination under the approved indication.

QDENGA in India

• Regulator: Central Drugs Standard Control Organisation (CDSCO).
• Indian approval: Marketing authorisation granted in July 2026.
• Approved age group: 4–60 years.
• Initially, the vaccine is expected to be available through the private sector.
• The price has not yet been announced.

QDENGA vs DengiAll

When Will QDENGA Be Available?

• QDENGA is expected to enter the Indian private market by mid-2027, subject to completion of regulatory and commercial processes.
• Takeda has partnered with Dr. Reddy’s Laboratories for distribution in India’s private paediatric and adult market.
• Pricing and possible inclusion in public immunisation programmes have not yet been announced.

Why Is QDENGA Important?

• Provides an additional tool for dengue prevention in India.
• Complements existing measures such as:
  • Aedes mosquito control
  • Elimination of mosquito breeding sites
  • Use of mosquito repellents and protective clothing
  • Early diagnosis and medical care
• Its broader public-health impact will depend on price, accessibility, uptake and future government policy.

UPSC IAS Live GS P2I Foundation 2027 Pratigya September Batch (Basic)

Sharing is caring!